Want to see GB:CIZ full AI Analyst Report?
CIZ Stock Chart & Stats
2.05 p
0.00 p(0.00%)
At close: 4:00 PM EDT
2.05 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range1.20 p - 3.90 p
Previous CloseN/A
Volume400.24K
Average Volume (3M)1.23M
Market Cap
£7.86M
Enterprise Value12.21M
Total Cash (Recent Filing)£116.00K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.65
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding424,963,200
10 Day Avg. Volume655,017
30 Day Avg. Volume1,232,506
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-18.07
Price to Sales (P/S)0.00
P/FCF Ratio-12.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageReported minimal debt lowers interest burden and reduces default risk for a pre-revenue biotech. Low leverage preserves flexibility to raise equity or grant-based funding and limits fixed obligations, supporting continuity of R&D investment during lengthy validation cycles.
Focused Clinical NicheA clear strategic focus on blood-based early lung cancer diagnostics creates a concentrated go-to-market path and expertise build-up. Structural demand for earlier cancer detection and potential linkage to screening programs support a durable addressable market if clinical validation succeeds.
Lean Operating BaseA very small headcount keeps fixed overhead low and enables capital-efficient operations while advancing development milestones. For a pre-commercial biotech, lean staffing can stretch runway, reduce cash burn per milestone, and allow selective outsourcing of costly trial activities.
Bears Say
Negative EquityEquity erosion to negative territory signals cumulative losses have consumed the capital base, weakening balance-sheet credibility. Negative equity constrains financing choices, can deter partners, and increases reliance on dilutive equity raises or non-dilutive grants to fund essential validation work.
Consistent Cash BurnPersistent negative operating cash flow indicates the company must secure external financing to sustain operations and progress trials. Ongoing burn depletes assets, raises dilution and funding-risk concerns, and could delay or constrain development timelines if capital is not obtained.
Pre-revenue ModelLack of revenue means value creation hinges entirely on successful clinical validation, regulatory clearance, and commercialization—multi-year, binary outcomes. This creates high execution risk, dependency on external funding, and uncertain timing for sustainable cash generation.
Cizzle Biotechnology Holdings PLC News
CIZ FAQ
What was Cizzle Biotechnology Holdings PLC’s price range in the past 12 months?
Cizzle Biotechnology Holdings PLC lowest share price was 1.20 p and its highest was 3.90 p in the past 12 months.
What is Cizzle Biotechnology Holdings PLC’s market cap?
Cizzle Biotechnology Holdings PLC’s market cap is £7.86M.
When is Cizzle Biotechnology Holdings PLC’s upcoming earnings report date?
Cizzle Biotechnology Holdings PLC’s upcoming earnings report date is Sep 24, 2026 which is in 50 days.
How were Cizzle Biotechnology Holdings PLC’s earnings last quarter?
Cizzle Biotechnology Holdings PLC released its earnings results on Apr 30, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Cizzle Biotechnology Holdings PLC overvalued?
According to Wall Street analysts Cizzle Biotechnology Holdings PLC’s price is currently Overvalued.
Does Cizzle Biotechnology Holdings PLC pay dividends?
Cizzle Biotechnology Holdings PLC does not currently pay dividends.
What is Cizzle Biotechnology Holdings PLC’s EPS estimate?
Cizzle Biotechnology Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cizzle Biotechnology Holdings PLC have?
Cizzle Biotechnology Holdings PLC has 424,963,200 shares outstanding.
What happened to Cizzle Biotechnology Holdings PLC’s price movement after its last earnings report?
Cizzle Biotechnology Holdings PLC reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.636%.
Which hedge fund is a major shareholder of Cizzle Biotechnology Holdings PLC?
Currently, no hedge funds are holding shares in GB:CIZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings Plc specializes in developing an advanced immunoassay diagnostic test. This innovative tool aims to identify the CIZ1B biomarker, facilitating the early detection of lung cancer. The company, previously known as Cizzle Biotechnology Limited, officially changed its corporate identity to Cizzle Biotechnology Holdings Plc in May 2021. Its main operational base is situated in London, United Kingdom.